Radiopharmaceutical developer Clarity Pharmaceuticals is highlighting the dosing of the first patient in the therapeutic phase of a clinical trial examining the effectiveness of the company's theranostic products.
The phase I/II trial, known as the SECuRE trial, is evaluating copper-64 (Cu-64) and copper-67 (Cu-67) SAR-bisPSMA theranostic products in patients with metastatic, castration-resistant prostate cancer. The first patient in the therapeutic phase was treated at the Urology Cancer Center and GU Research Network in Omaha, NE.
The trial advanced to the therapeutic stage after data reviewed by a safety review committee showed promise in the dosimetry phase with Cu-64 SAR-bisPSMA.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
